BIOD 531 / Ipsen - LARVOL DELTA

Biodel reports fourth quarter fiscal year 2013 financial results (Biodel Press Release) - "...look forward to delivering on several key milestones in 2014 including reporting top-line data from the BIOD-531 Phase 1 trial in the next calendar quarter, identifying analog-based ultra-rapid-acting insulin candidates and initiating pivotal trials on our glucagon program in the second half of 2014...reported a net loss for the three months ended September 30, 2013 of $0.8 million, or $0.04 per share of common stock,"

Anticipated new trial • Anticipated P1 data • Stock price • Diabetes